Biomedical Advanced Research and Development Authority (BARDA)
U.S. government authority within HHS/ASPR that funds and manages advanced research, development, acquisition, and manufacturing scale-up of medical countermeasures (vaccines, therapeutics, diagnostics, devices, and non-pharmaceutical products) for public health emergencies and chemical, biological, radiological, and nuclear (CBRN) threats. Operates competitive solicitations and pre-submission engagement, provides nonclinical and clinical development support, invests in domestic manufacturing and diagnostics infrastructure, and executes procurement and stockpiling for national preparedness.
Industries
Nr. of Employees
large (251-1000)
Biomedical Advanced Research and Development Authority (BARDA)
Washington, District of Columbia, United States, North America
Products
Medical Countermeasure Development
BARDA supports the development of medical countermeasures, including vaccines, drugs, and diagnostics, to address public health emergencies and bioterrorism threats.
Project BioShield
A program that provides funding and support for the development and procurement of medical countermeasures against chemical, biological, radiological, and nuclear threats.
Public Health Emergency Preparedness
BARDA works to enhance national preparedness for public health emergencies by collaborating with industry and government partners to develop and stockpile necessary medical resources.
Medical Countermeasure Development
BARDA supports the development of medical countermeasures, including vaccines, drugs, and diagnostics, to address public health emergencies and bioterrorism threats.
Project BioShield
A program that provides funding and support for the development and procurement of medical countermeasures against chemical, biological, radiological, and nuclear threats.
Public Health Emergency Preparedness
BARDA works to enhance national preparedness for public health emergencies by collaborating with industry and government partners to develop and stockpile necessary medical resources.
Services
Broad Agency Announcement (BAA) funding and solicitation management
Competitive solicitations for R&D proposals with multi-stage submission, technical evaluation, and award negotiation across BARDA program areas.
Contracting, procurement, and acquisition management
Acquisition services including contract formulation, award execution, other transaction agreements, portfolio management, and procurement support to enable development, manufacturing, and stockpiling of medical countermeasures.
Clinical Studies Network (CSN) services
Integrated clinical services including project management, study start-up, site selection and monitoring, lab services, regulatory/IRB support, data management, statistical analysis, and biospecimen storage provided via vetted CRO partners.
Diagnostics infrastructure investment and DxR2 rapid response
Funding and technical support to develop diagnostics, build domestic manufacturing capacity for rapid test production, and support deployment across laboratories, point-of-care, and home settings.
Preclinical testing services via program-run CRO engagements
Confidential preclinical evaluation services (e.g., efficacy testing for specific threats) provided through program contracts to evaluate candidate activity across relevant models and serotypes.
Broad Agency Announcement (BAA) funding and solicitation management
Competitive solicitations for R&D proposals with multi-stage submission, technical evaluation, and award negotiation across BARDA program areas.
Contracting, procurement, and acquisition management
Acquisition services including contract formulation, award execution, other transaction agreements, portfolio management, and procurement support to enable development, manufacturing, and stockpiling of medical countermeasures.
Clinical Studies Network (CSN) services
Integrated clinical services including project management, study start-up, site selection and monitoring, lab services, regulatory/IRB support, data management, statistical analysis, and biospecimen storage provided via vetted CRO partners.
Diagnostics infrastructure investment and DxR2 rapid response
Funding and technical support to develop diagnostics, build domestic manufacturing capacity for rapid test production, and support deployment across laboratories, point-of-care, and home settings.
Preclinical testing services via program-run CRO engagements
Confidential preclinical evaluation services (e.g., efficacy testing for specific threats) provided through program contracts to evaluate candidate activity across relevant models and serotypes.
Expertise Areas
- Advanced development and funding management for medical countermeasures
- Clinical trial network operations and CRO management
- Preclinical model and assay development for threat-specific evaluations
- Diagnostics and device development, scale-up, and rapid response manufacturing
Key Technologies
- Metagenomic next-generation sequencing (mNGS) for pathogen-agnostic detection
- Point-of-care and at-home diagnostic platforms
- Direct-from-specimen antimicrobial resistance testing
- mRNA and nucleic acid vaccine modalities